| In this study, we systematically analyzed the pharmacoeconomic literature of Western drugs commonly used in the clinical treatment of osteoporosis in the past two decades and evaluated their quality. By searching China Knowledge, Wanfang Data, Pubmed, and Web of Science databases, a total of 109 literature meeting the inclusion criteria were screened. The evaluation of the quality of the literature according to the CHEERS 2022 checklist revealed that the average score of the included literature was low, with only 3 pieces of literature of good quality, 16 pieces of literature of qualified quality, and 90 pieces of literature of unqualified quality. The main issues included lack of real data, long-term data, and diverse population studies. This study revealed the strengths and weaknesses of current pharmacoeconomic studies on osteoporosis and provided a reference for future high-quality studies with the aim of improving the economic efficiency of treatment, optimizing the allocation of health resources, and improving the quality of life of the patients. |